Prothrombin Complex Concentrate (PCC) for Non‐Vitamin K Oral Anticoagulant (NOAC) reversal: Good enough for now?

This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - Category: Hematology Authors: Tags: Commentary Source Type: research

Related Links:

AbstractData on LA/LAA thrombus resolution after rivaroxaban treatment has not been established. The aim of the present study was to compare the efficacy and safety on the resolution of LA/LAA thrombus between rivaroxaban and warfarin in nonvalvular atrial fibrillation (AF) patients. 80 AF patients with LA/LAA thrombus between January 2013 and June 2016 were randomized divided into warfarin group (n  = 40) and rivaroxaban group (n = 40). Compared to warfarin group, thrombin time (TT; p 
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
Publication date: Available online 16 May 2019Source: Journal of the Saudi Heart AssociationAuthor(s): Nasser Alali, Mahmoud Hassan Mahmoud, Mousa Ayesh Alharbi, Sami Nimer GhazalAbstractBackgroundEstablishment of thromboembolism prevention remains a challenge despite the widespread consensus that thromboprophylaxis safely reduces patient morbidity and mortality. Dabigatran is a nonvitamin K antagonist oral anticoagulant (NOAC) which reduces the risk of thromboembolism. Proper dosing is important to achieve the maximum prophylactic benefit with a maintained safety profile.ObjectiveTo evaluate the appropriateness of dabigat...
Source: Journal of the Saudi Heart Association - Category: Cardiology Source Type: research
Oral anticoagulation (OAC) is superior to antiplatelet therapy to prevent stroke in patients with atrial fibrillation (AF). In contrast, patients who have experienced an acute coronary event and/or coronary stent placement benefit from antiplatelet therapy to prevent future adverse cardiac events. While both of these cardiac conditions are highly prevalent on their own, they also frequently occur concurrently. In these situations, combined antiplatelet therapy and OAC significantly increases the risk of bleeding events [1,2].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
Publication date: Available online 24 May 2019Source: The Lancet HaematologyAuthor(s): Margarita Kushnir, Yun Choi, Ruth Eisenberg, Devika Rao, Seda Tolu, Jackson Gao, Wenzhu Mowrey, Henny H BillettSummaryBackgroundBecause studies of direct oral anticoagulants in patients with venous thromboembolism and non-valvular atrial fibrillation have had minimal representation of morbidly obese patients (ie, body-mass index [BMI] ≥40 kg/m2), their efficacy and safety in this population are unclear. We investigated whether apixaban and rivaroxaban are as effective and safe as warfarin in morbidly obese patients.MethodsWe did a sin...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Conclusion: Patients with prior stroke may be the preferred group for LAAC regardless of the presence or absence of contraindications for anticoagulant therapy.
Source: Cerebrovascular Diseases - Category: Neurology Source Type: research
Anticoagulant therapy is the most effective strategy to prevent arterial and venous thromboembolism, but treating older individuals is challenging, because increasing age, comorbidities, and polypharmacy increase the risk of both thrombosis and bleeding. Warfarin and non–vitamin K antagonist oral anticoagulants are underused and often underdosed in the prevention of stroke in older patients with atrial fibrillation because of concerns about the risk of bleeding. Poor adherence to anticoagulant therapy is also an issue for older patients with atrial fibrillation and those at risk of recurrent pulmonary embolism. In th...
Source: Blood - Category: Hematology Authors: Tags: How I Treat, Free Research Articles, Thrombosis and Hemostasis Source Type: research
Publication date: Available online 16 May 2019Source: Journal of the Saudi Heart AssociationAuthor(s): Nasser Alali, Mahmoud Hassan Mahmoud, Mousa Ayesh Alharbi, Sami Nimer GhazalAbstractBackgroundEstablishment of thromboembolism prevention remains a challenge despite the widespread consensus that thromboprophylaxis safely reduces patient morbidity and mortality. Dabigatran is a non-vitamin K antagonist oral anticoagulant (NOAC) which reduces the risk of thromboembolism. Proper dosing is important to achieve the maximum prophylactic benefit with a maintained safety profile.ObjectiveTo evaluate the appropriateness of dabiga...
Source: Journal of the Saudi Heart Association - Category: Cardiology Source Type: research
CONCLUSIONS: In the largest real-world practice study among Asians with NVAF, four DOACs were associated with lower risks of thromboembolism and bleeding than warfarin. There was consistency even amongst high risk subgroups and whether standard dose or low dose regimes were compared. PMID: 31103697 [PubMed - as supplied by publisher]
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
AbstractPurpose of ReviewAtrial fibrillation is cause for a growing burden of thromboembolic stroke. Transcatheter left atrial appendage closure is an alternative to lifelong oral anticoagulation for many patients with nonvalvular atrial fibrillation. Reviewed here are three commonly used devices (Watchman, Amplatzer Cardiac Plug/Amulet, and Lariat) and their key clinical trials, special candidate patient populations, and recent investigations of the impact of post-procedure antithrombotic strategies.Recent FindingsTranscatheter left atrial appendage closure devices provide noninferior thromboembolic stroke risk reduction ...
Source: Current Cardiovascular Risk Reports - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Bleeding | Coumadin | Hematology | Stroke | Thrombosis | Vitamin K | Vitamins | Warfarin